Ignite Creation Date:
2025-12-24 @ 10:12 PM
Ignite Modification Date:
2025-12-25 @ 7:47 PM
Study NCT ID:
NCT00280735
Status:
COMPLETED
Last Update Posted:
2017-07-11
First Post:
2006-01-19
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC
Sponsor:
UNC Lineberger Comprehensive Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2004-05
Start Date Type:
ACTUAL
Primary Completion Date:
2011-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2011-07
Completion Date Type:
ACTUAL
First Submit Date:
2006-01-19
First Submit QC Date:
None
Study First Post Date:
2006-01-23
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-03-24
Results First Submit QC Date:
None
Results First Post Date:
2017-06-12
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-06-09
Last Update Post Date:
2017-07-11
Last Update Post Date Type:
ACTUAL